Restore Medical News
8 articles
ראיון עם אחיו של החטוף עידן שתיוי שנרצח ב-7 באוקטובר, מקים סטארט-אפ בתחום הפוריות ● הבדל בין גברים ונשים בעיכול חלבונים ● ביולייט הודיעה על השלמת ניסוי קליני בו הראתה שהיא מצליחה לאבחן ניוון ראייה בנוזל דמעות ● גיוס של 23 מיליון דולר ל-Restore Medical בתחום אי ספיקת הלב ● אישור FDA לטכנולוגיה של Synchrony Medical לניקוי דרכי הנשימה ● השבוע בביומד
Omri Shtaywi, brother of a kidnapped and murdered individual, has founded a fertility startup named ERA. The startup aims to create life in response to the loss of his brother. ERA has developed a language model tailored for the fertility sector, aiming to streamline the complex processes involved in fertility treatments. The company has raised an initial funding of $500,000 from investors including Fusion, Avishai Abrahami, Omer Kaplan, and Eynat Guez. The startup is in the R&D stage and plans to expand in the US. The business model involves a community with B2B2C elements, offering a freemium model to consumers and connecting them with service providers.
InvestmentProduct StagePartners
Israeli startup Restore Medical raises $23 million to treat heart failure and has already begun clinical trials
Restore Medical Receives Breakthrough Device Designation from FDA for ContraBand™ System to Treat HFrEF Patients
Restore Medical, a leader in interventional cardiology, has received Breakthrough Device Designation from the FDA for its ContraBand™ device, aimed at treating heart failure with reduced ejection fraction (HFrEF). This designation is a significant milestone, highlighting the devices potential to address unmet needs in cardiac care. The ContraBand™ is a minimally invasive transcatheter Pulmonary Artery Banding system designed to improve the quality of life for HFrEF patients. The FDAs decision was based on promising results from an ongoing feasibility study. Restore Medical is backed by investors including Peregrine Ventures and the European Innovation Council, reflecting strong support for its innovative technology.
Investment
Restore Medical Announces Successful First-In-Human Preliminary Results of Its CONTRABAND™ System for Symptomatic Systolic Heart Failure Patients
Restore Medical Ltd, a medical device company, has completed enrollment for its First In Human clinical study with its CONTRABAND device. The device is a Pulmonary Artery Banding (PAB) transcatheter implant designed to treat heart failure with reduced ejection fraction (HFrEF) and improve the quality of life for heart failure patients. The study enrolled 15 patients across 5 European hospitals, all of whom experienced symptom improvement. The CONTRABAND device improved the quality of life of the treated patients and led to a reduction in the New York Heart Association (NYHA) heart class and improvement of left ventricle ejection fraction (LVEF).
InvestmentCustomers
Restore Medical secures €2.5 million in EU funding for cardiac implants to treat heart failure CTech
Restore Medical has been awarded a €2.5 million grant and a potential €10 million equity investment from the European Innovation Council (EIC) to support the development of its cardiac implants for the treatment of congestive heart failure. The company is running a First in Human clinical study in Europe with promising results. Restore Medical was one of the 74 winning companies selected out of 1,093 applicants for EIC funding. Congestive heart failure is a leading cause of mortality and hospital readmissions, affecting millions of people worldwide. Restore Medical was established in 2015 and is led by CEO Gilad Marom.
Investment
Revolutionary implant could ease congestive heart failure
Israeli startup Restore Medical has developed an implantable device called ContraBand to treat congestive heart failure (CHF). CHF affects millions of people globally and is a leading cause of mortality. The ContraBand implant is inserted into the pulmonary artery and supports the failed left ventricle by changing the pressure on the healthy right ventricle. The implant is not a cure for CHF but can reduce symptoms and hospitalizations. Restore Medical has conducted trials on animals and treated three human patients. The company plans to recruit more patients for clinical trials to seek regulatory approval. The CEO hopes to have a commercialized version of ContraBand available by 2026. The devices functionality is reversible, which is rare in the cardio implant world. Restore Medical has raised at least $1 million in funding.
Customers
Restore Medical successfully implants heart failure device
Israeli company Restore Medical has successfully implanted its product, ContraBand, in human patients for the first time. ContraBand is designed to treat heart congestion and is implanted using a minimally invasive procedure. The product aims to assist the failing left ventricle in patients with chronic left ventricular failure. Congestive heart failure is a progressive and debilitating disease, and Restore Medicals treatment has the potential to improve the quality of life for patients and reduce financial burdens. The company was established in 2015 and is backed by investors including Incentive Incubator, Peregrine Ventures, Allegro, and an undisclosed strategic investor.
Customers
Restore Medical Announces First in Human Trial for Treatment of Heart Failure in Patients
Restore Medical Ltd. announced promising preliminary results of the First-in-Human clinical trial of ContraBand™, a breakthrough treatment for patients suffering from congestive heart failure (CHF). The company successfully implanted the ContraBand™ in its first patients and the treatment is expected to relieve symptoms and improve patients quality of life. CHF affects millions of people worldwide and is considered a significant unmet clinical and financial need. Restore Medical Ltd. was established in 2015 and has developed a novel technology to improve the quality of life for patients with failing hearts.
Customers
